Horizon Discovery Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Horizon Discovery Ltd
Private Company Edition: In other $100m-plus venture capital rounds, Third Harmonic Bio emerged with $155m, including a new $105m series B round. Also, Europe- and Japan-focused Newton Biocapital launched its second VC fund with €50m in initial capital and a €150m fundraising goal.
Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.
Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine
Emerging Company Profile: Horizon Discovery’s former CEO Darrin Disley talks to Scrip about the importance of Mogrify’s revolutionary platform for converting cells into any state without the need to create stem cells and force them through evolutionary biology.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.